Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Anti-CD19/CD20 CAR-T cells in R/R DLBCL
NCT04486872Phase 1Unknown
- Sponsor
- First Affiliated Hospital, Zhejiang University School of Medicine
- Start
- Jul 2020
- Primary completion
- May 2022
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial in diffuse large B-cell lymphoma (DLBCL), sponsored by First Affiliated Hospital, Zhejiang University School of Medicine. Primary endpoint: Adverse Events at 12 months. Status: unknown.
02
Conditions
diffuse large B-cell lymphoma (DLBCL)
Beyond the preview
Go deeper on NCT04486872.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04486872.